OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Nikolaus Schultz, Jianjiong Gao et al.|JCO Precision Oncology|2017Cited by 2.7k
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> MutationsPaul K. Paik, Gregory J. Riely|Journal of Clinical Oncology|2011Cited by 689
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Paul K. Paik, Jeffrey W. Clark et al.|Nature Medicine|2020Cited by 393
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung CancerAdam J. Schoenfeld, Helena A. Yu, Dana Pe’er et al.|Clinical Cancer Research|2020Cited by 381
Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of <i>EGFR</i> / <i>KRA</i> S and Presence of <i>PIK3CA</i> / <i>AKT1</i> MutationsNatasha Rekhtman, Marc Ladanyi, Paul K. Paik et al.|Clinical Cancer Research|2012Cited by 365